Company research
KINETA, INC./DE
CIK 1445283Updated Sep 24, 2026
Name history
YUMANITY THERAPEUTICS, INC. · through Dec 16, 2022PROTEOSTASIS THERAPEUTICS, INC. · through Dec 16, 2020PROTEOSTASIS THERAPEUTICS INC · through Jun 2, 2011
Filing activity
Latest filing
50 filings on record · SCHEDULE 13G/A, 15-12G, 4, EFFECT, 8-K, S-8 POS.
About the company
Kineta, Inc. (OTC Pink: KANT) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. Kineta’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com.
Financials
FY 2024 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,019,000Source | 10,281,000Source | 17,435,000Source | 62,932,000Source |
| Property, Plant and Equipment, NetUSD | 0Source | 0Source | 249,000Source | 387,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 35,102,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 5,000,000Source |
| Assets, CurrentUSD | 1,019,000Source | 5,977,000Source | 13,600,000Source | 42,708,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 381,000Source | 119,000Source | 457,000Source | 1,207,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 472,000Source | 1,211,000Source | 18,543,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,886,000Source | 7,222,000Source | 12,865,000Source | 39,435,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 12,000Source | 10,000Source | 8,000Source | 11,000Source |
| Additional Paid in CapitalUSD | 170,878,000Source | 168,669,000Source | 156,106,000Source | 210,799,000Source |
| Retained Earnings (Accumulated Deficit)USD | -182,921,000Source | -165,789,000Source | -151,690,000Source | -187,313,000Source |
| Stockholders' Equity Attributable to ParentUSD | -12,031,000Source | 2,890,000Source | 4,424,000Source | 23,497,000Source |
| Liabilities and EquityUSD | 1,019,000Source | 10,281,000Source | 17,435,000Source | 62,932,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 12,886,000Source | 7,072,000Source | 11,487,000Source | 22,663,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 547,000Source | 843,000Source | 5,064,000Source |
| Accounts Payable, CurrentUSD | 3,901,000Source | 3,694,000Source | 6,635,000Source | 1,839,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | 547,000Source | 9,415,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 164,000Source | 169,000Source | 146,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,361,000Source | 2,211,000Source | 3,527,000Source | 4,846,000Source |
| Deferred Revenue, CurrentUSD | — | 0Source | 442,000Source | 5,061,000Source |
| Deferred Tax Liabilities, NetUSD | 49,000Source | 115,000Source | 213,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 779,000Source | — |
| Long-term Debt, Current MaturitiesUSD | — | — | — | 5,805,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 159,000Source | — | 7,357,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -17,137,000Source | -14,076,000Source | -63,453,000Source | -39,503,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 0Source | 9,000Source | 73,000Source | 631,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,240,000Source | 3,854,000Source | 5,169,000Source | 5,290,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 207,000Source | -2,941,000Source | -34,000Source | -5,545,000Source |
| Deferred Income Tax Expense (Benefit)USD | -2,896,000Source | -2,000,000Source | -6,923,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -11,567,000Source | -16,209,000Source | -19,029,000Source | -48,915,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | 331,000Source | 9,270,000Source | 3,093,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 0Source | 71,000Source | 138,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,347,000Source | 8,468,000Source | 11,808,000Source | -1,033,000Source |
| Repayments of Long-term DebtUSD | — | — | — | 2,267,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -5,220,000Source | -7,410,000Source | 2,049,000Source | -46,855,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 638,000Source | 5,858,000Source | 13,268,000Source | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 23,000Source | 48,000Source | 2,371,000Source | 1,298,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,240,000Source | 3,854,000Source | 5,188,000Source | 5,290,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | 341,000Source | 1,134,000Source |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | 0Source | 91,000Source | 62,000Source | — |
| General and Administrative ExpenseUSD | 8,145,000Source | 12,142,000Source | 8,696,000Source | 20,379,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| InterestExpenseNonoperatingUSD | -138,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -17,100,000Source | -14,099,000Source | -63,408,000Source | -39,503,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -5,000Source | 23,000Source | -45,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -39,503,000Source |
| Nonoperating Income (Expense)USD | -3,605,000Source | 1,647,000Source | -21,922,000Source | -758,000Source |
| Operating ExpensesUSD | 13,532,000Source | 21,165,000Source | 43,484,000Source | 46,789,000Source |
| Other Nonoperating Income (Expense)USD | -13,000Source | 99,000Source | 63,000Source | — |
| Payments of Financing CostsUSD | — | — | — | 103,000Source |
| Proceeds from Issuance of Common StockUSD | 500,000Source | 8,561,000Source | 1,581,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 1,419,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | 14,375,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 84,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | — | — | 8,044,000Source |
| Operating Income (Loss)USD | -13,532,000Source | -15,723,000Source | -41,531,000Source | -38,745,000Source |
| Other Nonoperating Income (Expense)USD | -13,000Source | 99,000Source | 63,000Source | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -5,000Source | 23,000Source | -45,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -17,100,000Source | -14,099,000Source | -63,408,000Source | -39,503,000Source |
| Earnings Per Share, BasicUSD per share | -1.42Source | -1.28Source | -12.87Source | — |
| Earnings Per Share, DilutedUSD per share | -1.42Source | -1.28Source | -12.87Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 12,100,000Source | 11,054,000Source | 4,926,000Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 12,100,000Source | 11,054,000Source | 4,926,000Source | — |
| Interest Expense (non-operating)USD | -138,000Source | — | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 0Source | 9,000Source | 100,000Source | — |
| General and Administrative ExpenseUSD | 8,145,000Source | 12,142,000Source | 8,696,000Source | 20,379,000Source |
| Interest ExpenseUSD | — | 337,000Source | 3,737,000Source | 1,817,000Source |
| Interest Income, OtherUSD | 111,000Source | 325,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -39,503,000Source |
| Nonoperating Income (Expense)USD | -3,605,000Source | 1,647,000Source | -21,922,000Source | -758,000Source |
| Operating ExpensesUSD | 13,532,000Source | 21,165,000Source | 43,484,000Source | 46,789,000Source |
| Research and Development ExpenseUSD | 5,387,000Source | 9,023,000Source | 15,928,000Source | 26,410,000Source |
Filing attachments
kant-ex99_1.htm · 8-K · 2025-07-01
EX-99.1 4 kant-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TuHURA Biosciences Completes Acquisition of Kineta Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody(mAb) to TuHURA’s late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025 Completion of the acquisition unlocks the fourth tranche of funds from $12.5 million aggregate PIPE financing announced June 3, 2025 TAMPA, Fla., Jun…
Read attachment ↗kant-ex99_1.htm · 8-K · 2025-06-24
EX-99.1 2 kant-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals TAMPA, Fla., and Seattle, Wash., June 23, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT) (“Kineta”), a clinical-stage biotechnology company foc…
Read attachment ↗kant-ex4_1.htm · 8-K · 2025-03-07
EX-4.1 2 kant-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗